Humanwell Healthcare (600079) Q1 2026 earnings summary

Executive summary

• Net profit attributable to shareholders rose 8.85% year-over-year to ¥588.17 million in Q1 2026.

• Total revenue slightly decreased by 0.59% year-over-year to ¥6.10 billion.

• Operating cash flow improved significantly, turning positive at ¥280.93 million from a negative ¥336.78 million a year ago.

Financial highlights

• Gross margin improved as operating costs decreased, with total operating costs at ¥5.22 billion, down from ¥5.34 billion year-over-year.

• Basic and diluted EPS both increased to ¥0.36, up 9.09% year-over-year.

• Weighted average ROE reached 3.07%, up 0.05 percentage points year-over-year.

• Total assets grew 2.36% to ¥37.61 billion compared to year-end 2025.

• Shareholders’ equity increased 2.66% to ¥19.42 billion.

Outlook and guidance

• Planned A-share issuance to controlling shareholder to raise ¥3–3.5 billion for R&D, manufacturing, digitalization, and working capital, pending shareholder approval.